微芯生物(688321.SH):未佈局微流控芯片用於癌症早篩
格隆匯3月11日丨微芯生物(688321.SH)在互動平臺表示,公司未佈局微流控芯片用於癌症早篩。在芯片相關應用方面,公司搭建了“基於化學基因組學的集成式藥物發現及早期評價平臺”,該核心技術平臺整合了分子醫學、計算機輔助藥物設計、藥物化學及組合化學、高通量高內涵藥物篩選、基因表達譜芯片(微陣列基因芯片)、生物信息學和化學信息學分析及軟件支持等內容,可有效地降低新藥的後期開發風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.